Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
2.340
+0.030 (1.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Dogwood Therapeutics Employees
Dogwood Therapeutics had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,431,256
Market Cap
3.12M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4 | 0 | - |
Dec 31, 2022 | 4 | -1 | -20.00% |
Dec 31, 2021 | 5 | 2 | 66.67% |
Dec 31, 2020 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
ReShape Lifesciences | 29 |
InMed Pharmaceuticals | 13 |
Entero Therapeutics | 9 |
NLS Pharmaceutics AG | 7 |
SCWorx | 7 |
Artelo Biosciences | 6 |
Titan Pharmaceuticals | 4 |
Tharimmune | 3 |
DWTX News
- 2 months ago - Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - GlobeNewsWire
- 4 months ago - Virios Therapeutics Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - GlobeNewsWire
- 5 months ago - Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - GlobeNewsWire
- 7 months ago - Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - GlobeNewsWire
- 7 months ago - Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - GlobeNewsWire
- 7 months ago - Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - GlobeNewsWire
- 8 months ago - Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript - Seeking Alpha